Neupro (Rotigotine) Patent Expiration, LOE Window & CMS Spending
Neupro (Rotigotine) by Ucb: FDA Orange Book LOE 2032-03-01, 0 AB generics, $94.5M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Ucb |
| FDA Application & Pathway | N021829 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2032-03-01 |
| Orange Book Patents (*PED Extensions) | 4 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $94.5M |
| 2024 Medicare Part D Spend | $90.1M |
| 2024 Medicaid Spend | $4.5M |
| Reported Wholesale Price Change (CA SB 17) | 6 WAC filings (max 18.3% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for UCB across sibling Meru public-data platforms.